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Abstract
Background: Our previous study had amplified antigen-specific full-length TCR a and b genes of clonally
expanded T cells in the peripheral blood (PB) of patients with diffuse large B-cell lymphoma (DLBCL). The transfer
of T cell receptor (TCR) genes endows T cells with new antigen specificity. Therefore, the aim of this study is to
generate diffuse large B cell lymphoma (DLBCL)-specific T cells by T cell receptor (TCR) gene transfer.
Materials and methods: Two different eukaryotic expression plasmids harboring TCR Va6 and TCR Vb13 genes
specific for DLBCL-associated antigens were constructed and subsequently transferred into human T cells using
Nucleofector™ technique. The expression of targeted genes in TCR gene-modified cells was detected by real-time
PCR, and western blot using TCR Vb antibody. The specific cytotoxicity of TCR gene-transferred T cells in vitro was
estimated using a lactate dehydrogenase (LDH) release assay.
Results: Two different eukaryotic expression plasmids harboring TCR Va6 and TCR Vb13 genes specific for DLBCL-
associated antigens were constructed and subsequently transferred into T cells from healthy donors. Specific anti-
DLBCL cytotoxic T lymphocytes (CTL) could be induced by transduction of specific TCR gene to modify healthy T
cells. The transgene cassette of TCR Vb13-IRES-TCR Va6 was superior to the other in the function of TCR-redirected
T cells.
Conclusions: Specific anti-DLBCL cytotoxic T lymphocyte (CTL) could be inducted by transduction of specific TCR
gene to modify healthy T cells.
Background
In the past two decades, fundamental advances in
immunology have introduced cellular-based therapies
for cancer patients [1,2]. Donor lymphocyte infusion
(DLI) has rendered or induced remission in relapsed
patients [3-5]. Autologous tumor-infiltrating lympho-
cytes (TILs) have been found to mediate objective can-
cer regression [6-8]. In recent years, specific adoptive
immunotherapy with tumor-specific cytotoxic T lym-
phocyte (CTL) has been considered a promising treat-
ment in malignancy, which might eradicate minimal
residual disease without increasing toxicity [9,10]. how-
ever, the generation of tumor-specific T cells in this
mode of immunotherapy is often limiting. The isolation
and in vitro expansion of antigen-specific T cell clones
remains time-consuming and labor-intensive, such that
this treatment is only available to a limited number of
patients. To overcome this limitation, another approach
has been developed for cancer immunotherapy based on
the genetic modification of normal T lymphocytes [11].
Because the molecular basis of CTL specificity is dic-
tated solely by its TCR, which consists of a heterodi-
meric pair of a-a n db-chains (TCRab), the molecular
transfer of TCR genes from donor to recipient T cells
using transgenic technology will result in a transfer of
CTL specificity [11,12]. Thus, TCR gene transfer is an
attractive strategy for the rapid in vitro generation of a
high number of antigen-specific T cells [13]. The first
TCR gene transfer into primary human T lymphocytes
was accomplished with work on melanoma antigen [14]
and CD8+T cells transduced with a TCR specific for
MART-1 were able to lyse an HLA-A2+melanoma cell
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ciated antigens (TAAs) have been selected as targets,
such as WT1 protein [15] and P53 protein [16]. In addi-
tion, TCR genes specific for HIV and EBV antigens have
also been transferred successfully into CD8+T cells from
patients [17,18]. In the first clinical trial of TCR gene
therapy [19] T cells that had been transduced with a
TCR specific for MART-1 mediated some degree of
cytotoxicity in 15 patients, demonstrating the feasibility
and potential of the anti-tumor effect of TCR gene-
modified T cells.
Diffuse large B cell lymphoma (DLBCL) is one of the
most common and highly aggressive lymphoid malig-
nancies whose clinical outcomes vary widely. Recently,
novel therapeutic strategies, including the incorporation
of immunotherapy and combined chemotherapy, have
improved the outcome for patients with DLBCL; e.g.,
the combination of rituximab (anti-CD20 antibody) and
CHOP regimen (R-CHOP) has been demonstrated to be
more effective [20]. Nonetheless, the increased toxicity
suggested that novel regimens should be developed to
improve long-term disease-free survival. The potential
for T cells to contribute to the eradication of B cell
malignancies in humans has been illustrated by the abil-
ity of allogeneic hematopoietic stem cell transplantation
to cure advanced lymphoma, which can be attributed in
part to a T cell mediated graft-versus-tumor (GVT)
effect. Therefore, much research has focused on the
generation of effective antigen-specific T cells. At pre-
sent, the successful transfer of TCR genes specific for a
variety of virus-specific and tumor-associated antigens,
such as MART-1/WT1 TCR-modified T cells, has been
shown to have specific cytotoxicity on melanoma or
leukemia cells [19,21]. However, little is known about
the TCR gene-modified T cells specific for lymphoma-
associated antigen.
Previously, we found specific TCR gene sequences
associated with DLBCL-associated antigen [22] and sub-
mitted them to GenBank (Accession numbers:
EU369627, EU368854, and so on). In the current study,
we developed two types of recombinant constructs con-
taining the HLA-A2-restricted TCR a6a n dT C Rb13
genes specific for DLBCL-associated antigens with TCR
a at either the IRES 5’ position or 3’ position, which
may induce DLBCL-specific T cells by TCR gene trans-
duction. TCR gene-transferred T cells exhibited specific
cytotoxicity in response to the DLBCL cell line. Using
this approach, we concluded that it is feasible to prepare
human tumor-specific T cells from polyclonally acti-
vated T cells if we could obtain MHC class I-restricted
TCR genes. This strategy will likely lead to individua-
lized immunotherapy based on lymphoma expressing
certain proteins in DLBCL.
Materials and methods
Construction of recombinant plasmids
DLBCL associated-TCR Va6a n dT C RV b13 chain
genes, which had been identified in peripheral blood T
cells from one DLBCL case were used [22]. Different
approaches were applied to construct two recombinant
plasmids containing the TCR Va6- and TCR Vb13-
chain genes specific for DLBCL-associated antigen.
Briefly, the full-length TCR a6a n db13 genes specific
for DLBCL-associated antigens were amplified by PCR
using forward primers (VA6-F, VB13-F) and reverse pri-
mers (VA6-R, VB13-R), respectively (Table 1), and
Table 1 The sequence of primers for PCR
Primers Function Sequences
Va6 Sense primer for TCR a6 genes 5’-TCCGCCAACCTTGTCATCTCCGCT-3’
Ca Antisense primer for TCR a6 genes 5’-GTTGCTCCAGGCCGCGGCACTGTT-3’
Vb13 Sense primer for TCR b13 genes 5’-CACTGCGGTGTACCCAGGATATGA-3’
Cb Antisense primer for TCR b13 genes 5’-CGGGCTGCTCCTTGAGGGGCTGCG-3’
VA6-F Sense primer for full-length TCR a6 genes 5’-GCCAGGTTCACCTCACAGTACAGAGTCC-3’
VA6-R Antisense primer for full-length TCR a6 genes 5’-GCAGAGGAAGGAGCGAGGGAGCAC-3’
VB13-F Sense primer for full-length TCR b13 genes 5’-GCACAGATACAGAAGACCCCTCCGTC-3’
VB13-R Antisense primer for full-length TCR b13 genes 5’-GGGTGAGGATGAAGAATGACCTGGGATG-3’
VA6-EF Sense primer for TCR a6 genes in the 5’ position of IRES 5’-ACGGAATTCGCCAGGTTCACCTCACAGTACAGAG-3’
VA6-MR Antisense primer for TCR a6 genes in the 5’ position of IRES 5’-TCGACGCGTTCAGAGGAAGGAGCGAGGGAGCAC-3’
VB13-SF Sense primer for TCR b13 genes in the 3’ position of IRES 5’-TTAGTCGACGCACAGATACAGAAGACCCCTCCGTC-3
VB13-NR Antisense primer for TCR b13 genes in the 3’ position of IRES 5-’TAATGCGGCCGCTCATGAGGATGAAGAATGACCTGGGATG-3’
VB13-EF Sense primer for TCR b13 genes in the 5’ position of IRES 5’-CGGAATTCGCACAGATACAGAAGACCCCTCCGTC-3’
VB13-MR Antisense primer for TCR b13 genes in the 5’ position of IRES 5’-TCCACGCGTTCAGTGAGGATGAAGAATGACCTGGGATG-3’
VA6-SF Sense primer for TCR a6 genes in the 3’ position of IRES 5’-TTGGTCGACGCCAGGTTCACCTCACAGTACAGAG-3’
VA6-NR Antisense primer for TCR a6 genes in the 3’ position of IRES 5’-TAATGCGGCCGCTCAGAGGAAGGAGCGAGGGAGCAC-3’
Note: Boldface with underline indicates restriction site; Italic with shadow indicates stop codon.
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tor pIRES, respectively, in which the TCR a6- and b13-
chain genes were linked by an internal ribosomal entry
site (IRES) to construct two different bicistronic eukar-
yotic expression plasmids (a6-IRES-b13, b13-IRES-a6)
with the a-o rt h eb-chain gene in the 5’ position and
the other gene in the 3’ position. The full-length TCRa-
and b-chain genes were ligated via EcoR I and Mlu I
restriction sites in the 5’ position of IRES, and via Sal I
and Not I restriction sites in the 3’ position. Two kinds
of TCR cassettes (Figure 1) were verified by restriction
analysis and sequencing.
Human CD3+T cell isolation and culture
Peripheral blood mononuclear cells (PBMCs) obtained
from three healthy donors (HLA-A2, DP restricted)
were isolated from heparinized venous blood by Ficoll-
Paque gradient centrifugation. All procedures were con-
ducted according to the guidelines of the Medical Ethics
Committee of the Health Bureau of Guangdong Pro-
vince of China. Cells were collected and washed twice in
Hank’s balanced salt solution, and then finally resus-
pended at a final concentration of 2 × 10
6 cells/mL in
complete RPMI 1640 medium (Invitrogen, Grand Island,
NY) supplemented with 10% heat-inactivated fetal calf
serum (FCS; HyClone, Logan, UT), 100 U/mL penicillin,
100 μg/mL streptomycin, 2 mM L-glutamine, and 50
μM 2-mercaptoethanol. CD3+T cells were positively
purified from freshly isolated PBMCs using CD3
+microbeads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) according to the manufacturer’sp r o t o c o l .T h e
purity of collected CD3+T cells was assessed by flow
cytometry. More than 95% of CD3+T cells were col-
lected by this technique. Initial stimulation was per-
formed at a concentration of 2 × 10
6 cells per well in
1 mL T cell complete medium (+200 IU/mL IL-2 and
2 μg/mL PHA [Sigma, USA]) for 24 h in non-tissue cul-
ture 12-well plates. Cells were washed once with med-
ium on the following day and then added to fresh
complete RPMI 1640 medium supplemented with
200 IU/ml IL-2. The culture medium was replaced every
2-3 days and the cells were cultured for 5-6 days before
transfection to achieve a high transfection efficiency.
Cell lines and culture
Toledo cells (human diffuse large B cell lymphomas cell
line, expressed DLBCL-associated antigen), Molt-4 cells
(human acute lymphoblastic leukemia cell line), Raji
cells (human Burkitt lymphoma cell line), all from
ATCC, were cultured in complete RPMI 1640 medium
supplemented with 10% heat-inactivated FBS and main-
tained at 37°C in a 5% CO2 incubator. The medium was
replaced every 2-3 days.
Transduction of TCR genes in T cells
Human CD3+T cells at 6 days after stimulation were
transfected using the Nucleofector™ technology (Amaxa,
Cologne, Germany). In brief, cells (5 × 10
6)w e r e
Figure 1 Schematic representation of plasmid constructs used in the present study. The structural pattern of two types of expression
cassettes of TCR a6- and b13-chain genes. The TCRa- and b-chain genes were introduced into the pIRES vector and linked by an IRES element.
For both linker elements, TCRa was integrated into either the 5’ position (aIb) or the 3’ position (bIa). A) TCR Va6-IRES-TCR Vb13 recombinant
plasmid. B) TCR Vb13-IRES-TCR Va6 recombinant plasmid. C) The structure of cassettes aIb and bIa.
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solution at room temperature from the human T cell
Nucleofector™ kit. Each plasmid (2 μg; including
TCR Va6-IRES-TCR Vb13 recombinant plasmid,
TCR Vb13-IRES-TCR Va6 recombinant plasmid, TCR
unloaded plasmid as a negative control, and maxGFP
as a positive control) was mixed with 0.1 mL cell sus-
pension and then transferred to a 2.0 mm electropora-
tion cuvette and nucleofected using an Amaxa
Nucleofector II apparatus according to the manufac-
turer’s guidelines. Storage of the cell suspension in
human T cell Nucleofector solution for longer than 20
min was avoided, as this reduces cell viability and gene
transfer efficiency. The cells were transfected using the
program T-020. The transfected T cells were trans-
ferred immediately to pre-warmed complete culture
medium and cultured in 12-well plates in a humidified
i n c u b a t o ra t3 7 ° Ca n d5 %C O 2. The culture medium
was changed 8 h after transfection to medium contain-
ing 200 IU/mL IL-2.
Determination of transfection efficiency
The transfection efficiency was estimated in each experi-
ment by scoring the number of GFP-positive cells
(maxGFP expression) 24 h after transfection. Immuno-
phenotyping analysis was performed using a TCR Vb13
monoclonal antibody (mAb) with laser confocal micro-
scopy (LCM; 510 META DuoScan, Carl Zeiss, Germany)
and by flow cytometry (FCM) 48 h after transfection.
Cells were stained with fluorescein isothiocyanate
(FITC)-conjugated mAbs. Antibodies were purchased
from Beckman Coulter, California, USA (mouse-anti-
human TCR Vb13).
RNA extraction and cDNA synthesis
Total RNA was extracted from the TCR CD3+T cells
that were either gene-transduced or not gene-trans-
duced, according to the manufacturer’sr e c o m m e n d a -
tions (TRIzol
® reagent; Invitrogen, USA). The quality of
RNA was analyzed by 0.8% agarose gel electrophoresis
with ethidium bromide staining. The RNA (2 μg) was
reverse-transcribed into first single-strand cDNA using
random hexamer primers, reverse transcriptase, and the
Superscript II kit (PowerScript™ Reverse, BD, USA)
according to the manufacturer’s instructions. The qual-
ity of cDNA was confirmed by reverse transcriptase
polymerase chain reaction (RT-PCR) for b2 microglubin
gene amplification.
Real-time PCR
The mRNA expressions of antigen-specific TCR Va6
and TCR Vb13 genes were detected by real-time PCR
using SYBR
® Green I with the Real Master Mix kit
(Tiangen, Beijing, China). Reactions were run in
triplicate and repeated in three independent experiments
using the MJ Research real-time PCR system (Bio-Rad,
USA) with a cDNA template in a 25 μL reaction under
the following conditions: 95°C for 2 min, followed by 45
cycles of 95°C for 15 s and 62°C for 1 min. The primers
used in the real-time PCR are listed in Table 1. Similar
manipulation was performed with RNA as the template
to exclude the presence of plasmid DNA.
Western blot analysis
CD3+T cells at 2 × 10
6 were harvested 3 days after trans-
fection, mixed with RIPA lysis buffer (1 × PBS, 1% Noni-
det P-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate [SDS], 10 mmol/L phenylmethylsulfonyl
fluoride, 1 μg/mL aprotinin, and 100 mmol/L sodium
orthovanadate), and incubated on ice for 30 min to iso-
late total proteins. Proteins (100 μg) were separated by
7.5% SDS-PAGE and transferred to nitrocellulose mem-
branes (Invitrogen, USA) using a damp-dry transfer
device (Bio-rad, USA). After blocking for 1 h in 5%
defatted milk powder in PBS, the membrane was washed
and then probed with 1:300 mouse-anti-human TCR
Vb13 monoclonal antibody (Beckman Coulter, USA).
Similar studies were performed with 1:500 mouse-anti-
human b actin (BOSTER, Wuhan, China). The antibodies
were detected using 1:10000 horseradish peroxidase-
conjugated rabbit-anti-mouse IgG (Tiangen, Beijing,
China). A Western blotting luminol reagent (Tiangen,
Beijing, China) was used to visualize the bands corre-
sponding to each antibody.
Cytotoxicity assay
TCR gene-transferred CD3+T cells (effector cells) or
TCR CD3+T cells that were not gene-transduced were
incubated with Toledo cells (DLBCL cell line, ATCC,
target cells), Molt-4 cells, or Raji cells in U-bottomed,
96-well microplates at 10:1 effector-target ratios for
10 h at 37°C and 5% CO2 in culture media containing
5% FBS for the in vitro cytotoxicity assay. Each effector-
target mixed condition was analyzed in triplicate and
repeated in three independent experiments (transferred
CD3+T cells from three healthy individuals). Cell-
mediated cytotoxicity was determined using a nonra-
dioactive lactate dehydrogenase (LDH) release assay
(Roche, Germany) according to the manufacture’s
instructions. Spontaneous LDH release from both target
and effector cells was subtracted from the measured
values and the final results were expressed as a percen-
tage of specific cytotoxicity. Percentage specific lysis was
calculated from LDH as follows: (experimental release-
target spontaneous release-effector spontaneous
release)/(target maximum release-target spontaneous
release). The Mann-Whitney test was used to determine
differences between two independent samples in
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P < 0.05.
Results
TCR plasmid construction
In our previous study, expanded TCR Va and TCR Vb
subfamily T cells were identified in the PB of patients
with DLBCL, which was presumed to have been driven
by the stimulation of epitopes in DLBCL [22]. The full-
length TCRVa6- and Vb13-chain genes specific for
DLBCL-associated antigen had been amplified for the
construction of bicistronic recombinant plasmids.
Because a gene inserted downstream of the IRES will be
expressed at a significantly lower level than one intro-
duced upstream [23] and the two chains may play none-
quivalent roles in antigen selection, we integrated the
TCRa gene into either the IRES 5’ position (TCR Va6-
IRES-TCR Vb13) or the 3’ position (TCR Vb13-IRES-
TCR Va6), generating two types of recombinant plas-
mids. Subsequently, their sequence and reading frame
were confirmed by restriction enzyme digestion analysis
and sequencing (data not shown).
TCR gene-modified CD3+T cells
The CD3+T cells were transfected with the respective
TCR-encoding expression plasmids using Nucleofector™
technology. After gene transfection, higher V expression
levels of Va6 and Vb13 gene were detected by real-time
PCR respectively(data not shown), and the correspond-
ing protein of TCR Vb13 chain was detected by SDS-
PAGE (Figure 2), because it is difficult to purchase the
human TCR Va subfamily antibodies in China, in this
study, we used the Vb13 antibody to confirm the
expression of transfected recombinant plasmid, by com-
bining the results from real-time PCR, it could be con-
cluded that antigen-specific TCR a6a n db13 genes
were well expressed in both types of transgene cassettes,
indicating that the recombinant plasmids had been con-
structed successfully and that the expression of exogen-
ous TCR a and b genes could be detected in the
transduced cells.
Influence of the transgene cassette on TCR expression
level in CD3+T cells
Human CD3+T cells were transduced with the recombi-
nant plasmids harboring the two transgenic cassettes.
Immunophenotyping analysis 48 h after transduction was
performed by LSM using TCR Vb13 mAbs (Figure 3).
The gene transfer efficiency was assessed by CD3+T cell
staining with antibodies directed against TCR Vb13 by
FCM 2 days after transduction (Figure 4). TCR a-chain
expression was not detected due to the lack of a Va6-
specific antibody. TCR CD3+T cells that were not trans-
duced served as a negative control. The percentage of
TCR gene-transduced cells revealed differences in gene
expression levels between the aIb transgene cassette and
the bIa transgene cassette. The surface expression of
exogenous TCRb from cassette bIa (48.5%; Figure 4B)
was superior to that of cassette aIb (39.4%; Figure 4C),
compared to ~1% in the control cells (Figure 4A). This is
most likely due to the poor expression of the TCR
b-chain gene in the 3’ position of the IRES linker relative
to the insertion in the 5’ position, although there was no
statistical significance between the gene expression in the
3’ and 5’ positions of the IRES (P = 0.21). Nevertheless,
this still indicates that the 3’ position of an IRES element
is an unprivileged position leading to suboptimal TCR
chain expression levels.
Functional tests of TCR transductants
Finally, we analyzed whether the surface expression
levels of exogenous TCR a or b achieved by the differ-
ent vector cassettes influence TCR function. Cassette
bIa achieved a higher transduction efficiency than did
cassette aIb. However, the positive cell populations of
about 48.5% (TCR Vb13 single-positive cells) with cas-
sette bIa cannot exclude the presence of mixed TCR
heterodimers having formed as the transgenic TCR
chains mispaired with endogenous chains. To further
characterize the function of TCR, we evaluated the
impact of these two different transgene cassettes on the
specific cytotoxicity of TCR gene-transduced CD3+T
cells. The cytotoxicity of TCR gene-transduced CD3+T
cells was determined using a nonradioactive LDH
release assay. The LDH level was analyzed following the
cocultivation of effector cells (TCR gene-transduced
CD3+T cells or CD3+T cells transduced with empty
plasmid) with target cells (Toledo, Molt-4, and Raji
cells). The specific cytotoxicity of the TCR gene-trans-
duced CD3+T cells against Toledo cells by cassette bIa
Figure 2 TCR Vb13 protein expression was detected in TCR
gene-transfected CD3+T cells by Western Blot analysis. Lane 1:
CD3+T cells transfected with TCR Va6-IRES-TCR Vb13 recombinant
plasmid; Lane 2: CD3+T cells transfected with TCR Vb13-IRES-TCR
Va6 recombinant plasmid; Lane 3: mononuclear cells from cord
blood expressing TCR Vb13 protein as a positive control; Lane 4:
CD3+T cells transfected with empty plasmid.
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0.014), suggesting that the TCR transgene vector bIa
yielded a better function of human antigen-specific
TCR-redirected T cells than did vector aIb. Cytotoxicity
of TCR gene-transduced CD3+T cells against Toledo
cells by two types of TCR transgene cassettes (aIb, P =
0.008; bIa, P = 0.000) was significantly higher than that
of CD3+T cells transduced with empty vector. From
these cocultivations of effector cells with target cells, we
found that the cocultivation of TCR gene-transduced
CD3+T cells with the Toledo cell line achieved the
highest LDH level (Figure 5), indicating that TCR
Figure 3 Antigen-specific TCR gene-transduced CD3+T cells from PB of healthy individuals stained with TCR Vb13-specific antibody
and imaged by LSM (×630). A) CD3+T cells transduced with Vb13-IRES-TCR Va6 recombinant plasmid and stained by FITC-TCR Vb13-
specific antibody. B) CD3+T cells transferred with empty vector as a negative control for exogenous TCR Vb13 expression.
Figure 4 The use of two TCR vector cassettes results in differential expression in human CD3+T cells. TCR gene-transduced CD3+T cells
were stained with a TCR Vb13-specific antibody and analyzed by flow cytometry. The numbers indicate the percentage of TCR Vb13-positive
cells. A) Human CD3+T cells transferred with empty vector as a negative control for exogenous TCR Vb13 expression. B) Human CD3+T cells
transferred with TCR Vb13-IRES-TCR Va6 recombinant plasmid were stained with a TCR Vb13-specific antibody 48 h after transduction. C) Human
CD3+T cells transferred with TCR Va6-IRES-TCR Vb13 recombinant plasmid were stained with a TCR Vb13-specific antibody 48 h after
transduction. The TCR Vb13 gene specific for DLBCL exhibited higher expression in TCR gene-transferred CD3
+T cells when the bIa vector
construct was used.
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against the DLBCL cell line.
Discussion
The successful transfer of genes encoding TCRab
chains, which recognize a variety of virus-specific and
tumor-associated antigens, into primary T cells was
demonstrated previously [11,12,24,25]. For clinical
applications of TCR-redirected T cells, the efficient
functional expression of the transgenic TCR is a prere-
quisite. The selection of an optimal transgenic cassette
o f f e r sas i m p l eo p t i o nt oe n h a n c ef u n c t i o n a lT C R
expression, as well as a means to explore more com-
plex modifications of TCR chain genes to obtain pre-
ferential pairing (murinization, additional cysteine
bonds) [26,27] or enhanced expression through codon
modification [28].
In general, TCR a-a n db-chain genes can be com-
m o n l yl i n k e db ya nI R E S .B e c a u s eag e n ei n s e r t e d
d o w n s t r e a mo ft h eI R E Sw i l lb ee x p r e s s e da ts i g n i f i -
cantly lower levels than one introduced to the upstream
position,
23 and the two chains may play nonequivalent
roles in antigen selection, we integrated TCRa into
either the IRES 5’ position (TCRVa6-IRES-Vb13) or the
3’ position (TCRVb13-IRES-Va6), and generated two
types of recombinant plasmids. Subsequently, we
compared the influence of the transgenic cassettes on
the expression and function of the TCR specific for
DLBCL-associated antigen and found that the applica-
tion of cassette bIa resulted in higher expression and
functionality of a human TCR when compared to that
observed with the use of cassette aIb.Y e t ,i ft h eP 2 A
element (2A element of porcine teschovirus) [29,30],
instead of the IRES element, were employed to link a
single TCRa-a n db-chain-encoding mRNA, then plas-
mid TCRb-P2A-TCRa may achieve higher TCR chain
expression and T cell function compared to the TCRb-
IRES-TCRa plasmid [31]. A potential problem with
using the P2A linker is that parts of the virus-derived
sequence might be presented by MHC I molecules,
making the transferred T cells a target for elimination
by the host’s immune system [31]. These findings may
have serious consequences for the design of TCR
expression cassettes, which are used to change the anti-
gen specificity of T cells employed for adoptive T cell
therapy.
Most of the known T cell-recognized epitopes are
those presented by MHC class I molecules to CD8+T
cells, and relatively few MHC class II tumor epitopes
have been identified. Thus, to date, most adoptive
immunotherapy approaches have focused on CD8
+ CTL.
However, the ability to transfer TCR genes between
Figure 5 Specific cytotoxicity of TCR gene-transduced CD3+T cells directed against Toledo cells as determined by LDH release assay.
Three days after transduction, TCR gene-transduced CD3+T cells by two different TCR transgene cassettes were cocultured with Toledo, Raji, or
Molt-4 cells at a 10:1 ratio for 10 h. Then, the LDH level in the supernatant was determined. The spontaneous release of LDH from both target
and effector cells was subtracted from the measured values and the final results are expressed as the percentage of specific cytotoxicity. *Mann-
Whitney test of two independent samples was used to determine differences between the various groups. Statistical significance was defined as
P < 0.05.
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+ and CD8
+ lympho-
cytes can be generated against the same specific targets,
offering concerted therapeutic strategies that can fully
utilize adoptive transfer [32-34]. Thus, in the current
study, we screened CD3+T lymphocytes (including CD3
+CD4+and CD3+CD8+T cells) as the recipient cells of
TCR gene transduction. In human subjects, normal
autologous T lymphocytes, transduced ex vivo with anti-
tumor associated antigen (TAA) and the TCR genes,
which were re-infused into cancer patients, persist and
express the transgene for a prolonged time in vivo and
mediate the durable regression of large established
tumors [19]. Ideally, TCR genes specific for DLBCL-
associated antigen should be transduced into autologous
T lymphocytes, which aim directly at autologous lym-
phoma cells. It is a pity that we were unable to obtain
patients’ autologous lymphoma cells as target cells. With
respect to the most commonly distributed human MHC
I molecule HLA-A2, we selected an HLA-A2-positive
DLBCL cell line (Toledo cell line) as the target cells.
Antigen-specific TCR gene-modified T cells acquired
the ability for DLBCL-specific cytotoxic capacity accord-
ing to in vivo cytotoxicity assays. The effect of the TCR
Vb13-IRES-TCR Va6 recombinant plasmid-transferred
T cells was superior to that of the TCR Va6-IRES-TCR
Vb13-transferred T cells; specifically, the cytotoxicity of
TCR-transferred T cells with cassette bIa directed to
the DLBCL cell line arrived at 30% 72 h after transduc-
tion, however, the TCR-modified T cells showed lower
cytotoxicity for Molt-4 and Raji cells, which do not
express DLBCL-associated antigen; the specific anti-
DLBCL activity might be confirmed in this study. As
tumor cells possess more than one TAA, it is possible
that there are multiple T cell clones specific for tumor
cells. Further genetic modification of PBLs with a few
specific TCRs may be beneficial.
This study suggests the therapeutic potential of geneti-
cally engineered cells for the biologic therapy of cancer.
However, in the present study, as first step to investigate
the expression and the effect of TCR Va6/Vb13 recom-
binant vectors in vitro, we used the transient expression
technique, in which the genes could expression only few
day after transfection, and we could conform that speci-
fic anti-DLBCL cytotoxic T lymphocyte (CTL) could be
induced by transduction of specific TCR gene to modify
healthy T cells. For the clinical application in future,
stable expression of transduced genes in T cells is
necessary and should be optimized the transfection
technique, maybe using different viral vectors.
In summary, to our knowledge, this is the first
demonstration of DLBCL-associated antigen-specific
TCR gene-modified T cells having acquired specific
cytotoxicity. However, the present study should be fol-
lowed by a large cohort of cytotoxicity assays for
different DLBCL cell lines to confirm its common anti-
DLBCL cytotoxicity, which was thought to target the
TAA of DLBCL. This study provides substantial new
data for a better understanding of the strategy of adop-
tive immunotherapy in DLBCL.
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